Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -431.46%-9.32M | -338.45%-3.71M | 29.47%-760.62K | 44.90%-5.11M | 18.53%-1.43M | 71.00%-1.75M | -114.26%-845.27K | -0.73%-1.08M | -154.55%-9.27M | -105.15%-1.75M |
| Net income from continuing operations | -352.92%-10.62M | -787.31%-5.74M | -2.74%-833.13K | 46.97%-5.09M | 55.83%-1.29M | 54.90%-2.35M | -33.61%-646.74K | 18.84%-810.92K | -139.60%-9.6M | -197.61%-2.92M |
| Operating gains losses | -36.99%-8K | -717.74%-18.63K | -89.60%1.03K | 159.45%31.19K | 126.40%24.06K | -111.54%-5.84K | 148.83%3.02K | 274.12%9.95K | -565.02%-52.46K | -348.71%-91.13K |
| Depreciation and amortization | 782.31%10.32K | 374.40%3.34K | 46.89%896 | -75.20%3.65K | 34.44%1.17K | -32.56%1.17K | -81.97%703 | -92.59%610 | -60.26%14.74K | -90.27%871 |
| Asset impairment expenditure | ---- | ---- | ---- | 182.98%152.7K | ---- | ---- | ---- | ---- | -78.37%53.96K | ---- |
| Remuneration paid in stock | 912.44%694.64K | 1,332.14%308.58K | 149.78%140.15K | 77.84%348.02K | 69.61%201.76K | 9.39%68.61K | 258.29%21.55K | 103.09%56.11K | 102.24%195.69K | 409.12%118.96K |
| Other non cashItems | 4.09%2.93K | 4.26%2.89K | 8.53%2.94K | 5,309.18%11.2K | --2.91K | --2.81K | 13,750.00%2.77K | 1,348.66%2.71K | 100.33%207 | --0 |
| Change In working capital | 14.53%600.76K | 866.36%1.74M | 78.47%-72.51K | -563.38%-561.22K | -148.34%-522.36K | 154.46%524.55K | -314.96%-226.57K | -231.17%-336.84K | 126.12%121.11K | 1,621.97%1.08M |
| -Change in receivables | 89.57%-6.55K | -906.22%-28.63K | -85.11%3.54K | 172.07%16.93K | 384.33%58.7K | -598.40%-62.72K | -4,922.03%-2.85K | 253.62%23.81K | -341.70%-23.5K | -178.76%-20.64K |
| -Change in prepaid assets | 115.79%17.44K | -1,202.10%-506.92K | 200.33%68.6K | -115.94%-297.08K | -107.38%-79.34K | 90.81%-110.43K | 30.56%-38.93K | -250.68%-68.38K | -11.63%-137.58K | 2,136.61%1.07M |
| -Change in payables and accrued expense | -15.46%589.86K | 1,329.42%2.27M | 50.51%-144.65K | -199.60%-281.07K | -1,971.02%-501.71K | 209.32%697.71K | -214.49%-184.79K | -122.10%-292.27K | 68.89%282.19K | 160.32%26.82K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -431.46%-9.32M | -338.45%-3.71M | 29.47%-760.62K | 44.90%-5.11M | 18.53%-1.43M | 71.00%-1.75M | -114.26%-845.27K | -0.73%-1.08M | -154.55%-9.27M | -105.15%-1.75M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -38.56K | -9.07%-167.26K | -3.27%-91.51K | 0 | -9.68%-153.36K | -31.20%-88.61K | ||||
| Capital expenditure reported | --0 | ---- | ---- | -1.91%-159.78K | -3.27%-91.51K | --0 | ---- | ---- | -18.24%-156.79K | -31.20%-88.61K |
| Net PPE purchase and sale | ---38.56K | ---- | ---- | -318.08%-7.48K | --0 | --0 | ---- | ---- | 147.50%3.43K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---38.56K | ---- | ---- | -9.07%-167.26K | -3.27%-91.51K | --0 | ---- | ---- | -9.68%-153.36K | -31.20%-88.61K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 592.38%19.98M | -47.42%4.86M | 20.71%1.98M | -36.84%2.89M | 0 | 0 | 75.89%9.25M | -45.26%1.64M | ||
| Net issuance payments of debt | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | 66.67%-10.13K | --0 |
| Net common stock issuance | 590.66%21.21M | ---- | ---- | -35.00%5.35M | --2.28M | -37.12%3.07M | ---- | ---- | 50.65%8.23M | --0 |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | --0 | --0 | --0 | ---- | ---- | 4,102.34%1.59M | 4,075.37%1.58M |
| Net other financing activities | ---1.4M | ---- | ---- | 13.27%-486.56K | -621.33%-302.13K | ---- | ---- | ---- | -164.01%-561.01K | 141.42%57.96K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 592.38%19.98M | ---- | ---- | -47.42%4.86M | 20.71%1.98M | -36.84%2.89M | --0 | --0 | 75.89%9.25M | -45.26%1.64M |
| Net cash flow | ||||||||||
| Beginning cash position | 2,486.18%9.88M | -7.07%1.21M | -17.21%1.97M | -6.69%2.38M | -41.43%1.51M | -90.60%381.91K | -11.60%1.3M | -6.69%2.38M | 137.61%2.55M | 434.87%2.58M |
| Current changes in cash | 838.27%10.62M | 1,040.92%8.67M | 29.47%-760.62K | -139.93%-409.89K | 324.54%457.29K | 176.58%1.13M | -135.57%-921.02K | -0.02%-1.08M | -111.56%-170.84K | -109.84%-203.65K |
| End cash Position | 1,253.92%20.5M | 2,486.18%9.88M | -7.07%1.21M | -17.21%1.97M | -17.21%1.97M | -41.43%1.51M | -90.60%381.91K | -11.60%1.3M | -6.69%2.38M | -6.69%2.38M |
| Free cash from | -433.66%-9.36M | -311.02%-3.79M | 29.47%-760.62K | 44.04%-5.27M | 17.48%-1.52M | 71.00%-1.75M | -99.06%-921.02K | -0.73%-1.08M | -149.28%-9.42M | -99.73%-1.84M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.